Clinical Trials on GEP Neuroendocrine Tumor in Germany

Total 927 results

Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Gastro-enteropancreatic Neuroendocrine Tumor

Spain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
Camurus AB

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Gastro-enteropancreatic Neuroendocrine Tumor

United States, Belgium, Spain, Netherlands, France, Germany, Israel, Italy, Canada, Australia, Romania, Hungary
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (COOPERATE-1)

Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Germany
Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
Johannes Gutenberg University Mainz
Ipsen; Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA...

Active, not recruiting

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Cancer

Germany
Johannes Gutenberg University Mainz
Merck KGaA, Darmstadt, Germany

Completed

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy (AveNEC)

Cancer

Germany
University Medical Center Goettingen

Recruiting

Pelvic Cancer Registry for Online Adapted Radiotherapy (PRoART)

Pelvic Tumor | Thoracic Tumor

Germany
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
Wuerzburg University Hospital

Recruiting

PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms) (GIPSMA)

Gastrointestinal Cancer

Germany
Philogen S.p.A.
Immatics Biotechnologies GmbH

Terminated

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Merkel Cell Carcinoma

Germany, Austria, Denmark, France, Spain, United Kingdom
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

United States, Spain, Germany, Japan, France
Novartis Pharmaceuticals

Completed

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Metastatic Melanoma and Merkel Cell Carcinoma

Germany, Switzerland
University Hospital, Tours
European Academy of Dermatology and Venerology

Not yet recruiting

SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines (SUMMERTIME)

Merkel Cell Carcinoma

United Kingdom, Austria, Finland, France, Germany, Italy, Netherlands, Romania, Sweden, Turkey
Prof. Dr. med. Dirk Schadendorf
Bristol-Myers Squibb

Active, not recruiting

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (ADMEC-O)

Merkel Cell Carcinoma

Germany, Netherlands
Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Karsten Gavenis

Recruiting

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma

Germany, Austria
Ipsen

Terminated

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours (PRELUDE)

Neuroendocrine Tumours

United Kingdom, France, Germany, Australia, Italy
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Melanoma

Germany
Bristol-Myers Squibb

Active, not recruiting

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy (NICO)

Melanoma

Germany
4SC AG

Completed

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
Novartis Pharmaceuticals

Completed

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (MACS2002)

Neuroendocrine Tumors

Germany
University Hospital Tuebingen
Dermatologic Cooperative Oncology Group

Completed

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Melanoma

Germany
University Hospital Tuebingen

Completed

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Malignant Melanoma

Germany
University Hospital Tuebingen

Completed

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

Malignant Melanoma

Germany
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Advanced Melanoma

Germany
National Center for Tumor Diseases, Heidelberg
University Hospital Heidelberg

Completed

Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (CTLA4 NY-ESO-1)

Metastatic Melanoma

Germany
University Hospital Tuebingen
German Research Foundation

Completed

Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

Malignant Melanoma

Germany
Charite University, Berlin, Germany

Unknown

Multiepitope Peptide Vaccination in Melanoma

Metastatic Melanoma

Germany
University Hospital Tuebingen

Completed

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

Malignant Melanoma

Germany
Universitätsklinikum Hamburg-Eppendorf

Completed

Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma

Ependymoma | Medulloblastoma, Childhood | Cerebral Primitive Neuroectodermal Tumor

Germany
Universitätsklinikum Hamburg-Eppendorf

Completed

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Brain and Central Nervous System Tumors

Germany
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Pancreatic Neoplasms | Neuroendocrine Tumor | Neuroendocrine Carcinoma | Islet Cell Carcinoma

United States, Canada, Spain, Argentina, Germany, Belgium, Italy, France, Sweden, Australia, Netherlands
Universitätsmedizin Mannheim

Completed

Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy (ImmunoPAX)

Immuno-monitoring

Germany
Charite University, Berlin, Germany

Unknown

Study of Metastatic Ocular Melanoma

Ocular Melanoma

Germany
University of Regensburg
ClinAssess GmbH

Unknown

Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

Advanced Melanoma

Germany
University of Regensburg

Unknown

Immune Monitoring in Metastatic Melanoma

Metastatic Melanoma

Germany
University Hospital Tuebingen

Unknown

Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI

Malignant Melanoma Stage IV

Germany
University Hospital Tuebingen
Charite University, Berlin, Germany; University Hospital Heidelberg

Completed

FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA) (FLIMMA)

Melanoma | Moles

Germany
University Hospital Heidelberg
Department of Dermatology, Heidelberg University Hospital

Completed

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)

Melanoma | Exercise | PD-1 Antibodies

Germany
BioNTech SE

Completed

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)

Melanoma

Germany
Krankenhaus Nordwest

Terminated

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Chemo-refractory Melanoma

Germany
Ruhr University of Bochum

Completed

Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

Malignant Melanoma | Naevi

Germany
University Hospital Schleswig-Holstein
University Hospital Freiburg

Unknown

Identification of Biomarker Profiles GEP-NEN Patients

Neuroendocrine Tumors

Germany
Zentralklinik Bad Berka

Completed

Best Therapy for Patients With Neuroendocrine Tumors (BESTTHERAPYNET)

Neuroendocrine Tumors

Germany
University Hospital Erlangen

Completed

Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

Melanoma (Skin)

Germany
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
University Hospital Erlangen

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

Germany

Clinical Trials on GEP Neuroendocrine Tumor in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations